Role of selenium, iron, copper, and zinc in parkinsonism

Oxidative Stress and Neurodegenerative Disorders

Volumn , Issue , 2007, Pages 719-735

  Qureshi, G Ali ^a   Syed, Shuja Ali ^b   Parvez, S H ^c  

^a LIAQUAT UNIVERSITY OF MEDICAL AND HEALTH SCIENCES   (Pakistan)

^b SCUNTHORPE GENERAL HOSPITAL   (United Kingdom)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79251629603     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044452809-4/50171-X     Document Type: Chapter

References (94)

1. W Mok, TW Chow, L Zheng, WJ Mack and C Miller (2004) Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians. Am J Alzheimers Dis Other Demen. 19(3), 161-165.
2. B Ritz and F Yu (2000) Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol. 29 323-329.
3. GA Qureshi, SA Memon and SH Parvez (2004) Role of cobalamin and its impact on free radical NO homocysteine in Parkinsons on and off patients. Biog Amine 19(1), 26-44.
4. KA Jellinger (2003) General aspects of neurodegeneration. J Neural Transm. 65 101-144.
5. GM Cohen and D.M. D'Arcy Doherty M (1987) Free radical mediated cell toxicity by redox cycling chemicals. Br J Cancer 8 46-52.
6. PT Pugliese (1998) The skin's antioxidant systems. Dermatol Nurs. 10 401-416.
7. Cancer Res. 42 1955-1961.
8. D Guo, J Ling, MH Wang, JX She, J Gu and CY Wang (2005) Physical interaction and functional coupling between ACDP4 and the intracellular ion chaperone COX11, an implication of the role of ACDP4 in essential metal i. Mol Pain 1(1), 15-21.
9. AM Lin, SF Fan, DM Yang, LL Hsu and CH Yang (2003) Zinc-induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3. Free Radic Biol Med. 34(11), 1416-1425.
10. G Perry, LM Sayre, CS Atwood, RI Castellani, AD Cash, CA Rottkamp and MA Smith (2002) The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs 16(5), 339-352.
11. GA Qureshi and SH Parvez (1998) The role of aspartic acid, glutamic acid and GABA in neurologic disorders. Biog Amines 13(6), 565-578.
12. GA Qureshi, C Collins, SA Memon and H Parvez (2004) Parkinson's Disease and neurotransmitters interplay in On/Off phenomena. Biog Amines 19(2), 44-62.
13. B Chance, H Sies and A Boveris (1979) Hydroperoxide metabolism in mammalian organs. Physiol Rev. 59 527-605.
14. MM Zaleska and RA Floyd (1985) Regional lipid peroxidation in rat brain in vitro: possible role of endogenous iron. Neurochem Res. 10 397-410.
15. RA Floyd and JM Carney (1992) Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol. 32 S22-S27.
16. MM Zaleska, K Nagy and RA Floyd (1989) Iron-induced lipid peroxidation and inhibition of dopamine synthesis in striatum synaptosomes. Neurochemistry 14 597-605.
17. D Strausak, JF Mercer, HH Dieter, W Stremmel and G Multhaup (2001) Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res Bull. 55(2), 175-185.
18. OA Levander (1988) Selenium, chromium and manganese. ME Shils, MR Young,(Eds) Modern Nutrition in health and Disease Philadelphia: Lea 7 Febiger 227-263.
19. R Brigelius-Flohe, D Kluth and A Banning (2005) Is there a future for antioxidants in atherogenesis? Mol Nutr Food Res. 49(11), 1083-1089.
20. Ann Neurol. 32 804-812.
21. E Kienzl, L Punchingar, K Jellinger, W Linert, H Stachelberger and RF Jameson (1995) The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci. 134 69-78.
22. FJ Jimenez-Jimenez, JA Molina, MV Aguilar, I Meseguer, CJ Mateos-Vega, MJ Gonzalez-Munoz, F Bustos, A Martinez-Salio, M Orti-Pareja, M Zurdo and MC Martinez-Para (1998) Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J Neural Transm. 105(4-5), 497-505.
23. AJ Huges, SE Ben-Shlomo, ST Daniel and AJ Lees (1992) What features improve the accuracy of clinical diagnosis in Parkinson's disease? A clinopathalogical study. Neurology 42 1142-1146.
24. MM Hoehn and MD Yahr (1967) Parkinsonism: Onset, progression and mortality. Neurology 17 427-442.
25. DT Dexter, J Sian, S Rose, JG Hindmarsh, VM Mann and JM Cooper (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol. 35(1), 38-44.
26. KJ Thompson, S Shoham and JR Connor (2001) Iron and neurodegenerative disorders. Brain Res Bull. 55 155-164.
27. Y He, PS Thong, T Lee, SK Leong, CY Shi, PT Wong, SY Yuan and F Watt (1997) Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study. Brain Res. 735(1), 149-153.
28. JA Temlett, JP Landsberg, F Watt and JW Grime (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microana. J Neurochem. 62 134-146.
29. E Oestreicher, GJ Sengstock, P Riederer, CW Olanow, AJ Dunn and GW Arendash (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660 8-18.
30. M Hashimoto, LJ Hsu and Y Xia (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport. 10 717-721.
31. SR Paik, HJ Shin, JH Lee, CG Chang and J Kim (1999) Copper (II) -induced self-oligomerization of alpha-synuclein. Biochem J. 340(Pt 3), 821-828.
32. G Munch, HJ Luth, A Wong, T Arendt, E Hirsch, R Ravid and P Riederer (2000) Crosslinking of alpha-synuclein by advanced glycation endproducts-an early pathophysiological step in Lewy body formation? J Chem Neuroanat. 20(3-4), 253-257.
33. N Ostrerova-Golts, L Petrucelli, J Hardy, JM Lee, M Farer and B Wolozin (2000) The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci. 20 6048-6054.
34. E Sofic, P Riederer, H Heinsen, H Beckmann, GP Reynolds, G Hebenstreit and MB Youdim (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 74(3), 199-205.
35. E Sofic, W Paulus, K Jellinger, P Riederer and MB Youdim (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem. 56 978-982.
36. DT Dexter, FR Wells and A.J. Lees AJ et al (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem. 52 1830-1836.
37. PD Griffiths, BR Dobson, GR Jones and D.T.I.P. Clarke DT. Iron in the basal ganglia in Parkinson's disease (1999) An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain 122 667-673.
38. P Riederer, A Dirr, M Goetz, E Sofic, K Jellinger and MB Youdim (1992) Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol. 32 S101-S104. (Suppl.)
39. G Becker, J Seufert, U Bogdahn, H Reichmann and K Reiners (1995) Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45 182-184.
40. D Berg, G Becker, B Zeiler, O Tucha, E Hofmann, M Preier, P Benz, W Jost, K Reiners and KW Lange (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53(5), 1026-1031.
41. P Ryvlin, E Broussolle, H Piollet, F Viallet, Y Khalfallah and G Chazot (1995) Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol. 52(6), 583-588.
42. G Bartzokis, JL Cummings, CH Markham, PZ Marmarelis, LJ Treciokas, TA Tishler, SR Marder and J Mintz (1999) MRI evaluation of brain iron in earlier-and later-onset Parkinson's disease and normal subjects. Magn Reson Imaging 17(2), 213-222.
43. JM Gorell, RJ Ordidge, GG Brown, JC Deniau, NM Buderer and JA Helpern (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 45(6), 1138-1143.
44. DT Dexter, A Carayon, M Vidailhet, M Ruberg, F Agid, Y Agid, AJ Lees, FR Wells, P Jenner and CD Marsden (1990) Decreased ferritin levels in brain in Parkinson's disease. J Neurochem. 55 16-20.
45. K Jellinger, W Paulus, I Grundke-Iqbal, P Riederer and MB Youdim (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Disord Dement Sect. 2(4), 327-340.
46. VM Mann, JM Cooper, SE Daniel, K Srai, P Jenner, CD Marsden and AH Schapira (1994) Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol. 36(8), 876-881.
47. P Riederer, E Sofic and W.D. Rausch WD et al (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 52 515-520.
48. KL Double, M Maywald, M Schmittel, P Riederer and M Gerlach (1998) In vitro studies of ferritin iron release and neurotoxicity. J Neurochem. 70(6), 2492-2499.
49. D Ben-Shachar, R Zuk and Y Glinka (1995) Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem. 64 718-723.
50. D Sulzer, J Bogulavsky, KE Larsen, G Behr, E Karatekin, MH Kleinman, N Turro, D Krantz, RH Edwards, LA Greene and L Zecca (2000) Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci. USA. 97 11869-11874.
51. D Ben-Shachar, P Riederer and MB Youdim (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem. 57 1609-1614.
52. B Halliwell (1992) Reactive oxygen species and the central nervous system. J Neurochem. 59(5), 1623-1627.
53. VL Dawson and TM Dawson (1996) Nitric oxide neurotoxicity. J Chem Neuroanat. 10(3-4), 179-190.
54. M Gerlach, D Ben-Shachar, P Riederer and MB Youdim (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem. 63(3), 793-807.
55. Z Naturforsch. 58(9-10), 752-758.
56. J Lan and DH Jiang (1997) Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm. 104(6-7), 649-660.
57. S Bharath, M Hsu, D Kaur, S Rajagopalan and JK Andersen (2002) Glutathione, iron and Parkinson's disease. Biochem Pharmacol. 64(5-6), 1037-1048.
58. P Ponka (2004) Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann N Y Acad Sci. 1012 267-281.
59. JK Andersen (2004) Iron dysregulation and Parkinson's disease. J Alzheimers Dis. 6(Suppl. 6), S47-S52.
60. KJ Thompson, S Shoham and JR Connor (2001) Iron and neurodegenerative disorders. Brain Res Bull. 55(2), 155-164.
61. KR Wagner, FR Sharp, TD Ardizzone, A Lu and JF Clark (2002) Heme and iron metabolism: role in cerebral hemorrhage. J Cereb Blood 91(1), 9-18.
62. GA Qureshi, SA Memon, AA Qureshi, C Collin and SH Parvez (2003) Neurotoxicity and dynamic Parkinson's patients in on-off phenomena. Biog Amines 18(1), 55-78.
63. ZM Qian and X Shen (2001) Brain iron transport and neurodegeneration. Trends Mol Med. 7(3), 103-108.
64. RR Crichton, S Wilmet, R Legssyer and RJ Ward (2002) Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem. 91(1), 9-18.
65. BS Polla (1999) Therapy by taking away: the case of iron. Biochem Pharmacol. 57(12), 1345-1349.
66. J Salazar, N Mena and MT Nunez (2006) Iron dushomeostatsis in Parkinson's disease. J Neural Transm. 71 205-213.
67. BN Patel, RJ Dunn, SY Jeong, Q Zhu, JP Julien and S David (2002) Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci. 22(15), 6578-6586.
68. BS Connor, P Snyder, DA Arosio, P Loeffler and W.A. Le Witt A (1995) Quantitative analysis of isoferritins in select regions of aged, parkinsonian and Alzheimer's diseased brains. J Neurochem. 65 717-724.
69. DT Dexter, A Carayon, F Javoy-Agid, Y Agid, FR Wells, SE Daniel, AJ Lees, P Jenner and CD Marsden (1991) Alter-ations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 1953-1975.
70. J Kehrer (2000) The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149 43-50.
71. M Bergomi, M Vinceti, G Nacci, V Pietrini, P Bratter, D Alber, A Ferrari, L Vescovi, D Guidetti, P Sola, S Malagu, C Aramini and G Vivoli (1999) Environmental exposure to trace elements and risk of amyotrophic lateral sclerosis: a population-based case-control study. Environ Res. 89(2), 116-123.
72. M Iwata, A Hiraho and JH French (1979) Degeneration of the cerebellar system in X-chromosome-linked copper malabsorption. Ann Neurol. 5 542.
73. AW Zimmerman, J-M Matthieu, RH Quarles, RO Brady and JM Hsu (1976) Hypomyelination in copper-deficient rats: Prenatal and postnatal copper replacement. Arch Meurol. 33(2), 111.
74. DM Williams (1982) Clinical significance of copper deficiency and toxicity in the world population Current Topics in Nutrition and Disease. AS Prasad,(Eds) Alan R Liss Inc 277-299. Clinical, Biochemical, and Nutritional Aspects of Trace Elements
75. BL O'Dell (1982) Biochemical basis of the clinical effects of copper deficiency. AS Prasad,(Eds) Clinical Biochemical, and Nutritional Aspects of Trace Elements Current Topics in Nutrition and Disease Vol. 6 New York, US: Alan R Liss Inc 301-313.
76. CG Graham and A Cordano (1976) Copper deficiency in human subjects. AS Prasad,(Eds) Zinc and Copper Trace Elements in Human Health and Disease Vol. I New York: Academic Press 363.
77. D Benton (2002) Selenium intake, mood and other aspects of psychological functioning. Nutr Neurosci. 363-374 6
78. AR White and R Cappai (1996) Neurotoxicity from glutathione depletion is dependent on extracellular trace copper. J Neurosci Res. 71(6), 889-897.
79. BJ Tabner, S Turnbull, OM El-Agnaf and D Allsop (2002) Formation of hydrogen peroxide and hydroxyl radicals from A (beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkin. Free Radic Biol Med. 32(11), 1076-1083.
80. Z Yu, AJ Bruce-Keller, Y Goodman and MP Mattson (1998) Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res. 53(5), 613-625.
81. Lab Invest. 78(11), 1415-1429.
82. JJ Mitchell, M Paiva and MB Heaton (1999) Vitamin E and beta-carotene protect against ethanol combined with ischemia in an embryonic rat hippocampal culture model of fetal alcohol syndrome. Neurosci Lett. 263(2-3), 189-192.
83. MA Cotter, A Love, MJ Watt, NE Cameron and KC Dines (1995) Effects of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia 38(11), 1285-1294.
84. LM Gaetke and CK Chow (2003) Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 189(1-2), 147-163.
85. MP Cuajungeo and GJ Less (1997) Zinc metabolisam in the brain: tolerance to human neuro degenerative disorder. Neuro Dis. 4 137-169.
86. WL McKeehan, WG Hamilton and RG Ham (1976) Selenium is an essential trace nutrient for growth of WI-38 diploid human fibroblasts. Proc Nat Acad Sci. USA 73 2023.
87. YC Awasthi, E Beutler and SK Srivastava (1975) Purification and properties of human erythrocyte gluthatione peroxidase. J Biol Chem. 250 5144.
88. X Chen, GQ Yang, X Chen, Z Wen and K Ge (2003) Studies on the relationship of selenium and Keshan disease. Biol Trace Elem Res. 2 91.
89. MF Robinson (1982) Clinical effects of selenium deficiency and excess. AS Prasad,(Eds) Clinical, Biochemical, and Nutritional Aspects of Trace Elements New York, US: Alan Liss Inc 325-343.
90. OA Levander (1982) Selenium: biochemical actions, interactions, and some human health implications. AS Prasad,(Eds) Clinical, Biochemical, and Nutritional Aspects of Trace Elements New York, US: Alan Liss Inc 345-368.
91. EJ Underwood (1977) Trace Elements in Human and Animal Nutrition. 4th Edition New York: Academic Press pp. 302-346
92. E Grunblatt, S Mandel, G Maor and MB Youdim (2001) Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J Neurochem. 78 1-12.
93. S Mandel, E Grunblatt and MB Youdim (2000) cDNA microarray to study gene expression of dopaminergic neu-rodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopat. J Neural Transm Suppl. 60 117-124.
94. W Slikker Jr., S Jonas, RN Auer, GC Palmer, T Narahashi, MB Youdim, KI Maynard, KM Carbone and B Trembly (2001) Neuroprotection: past successes and future challenges. Ann N Y Acad Sci. 939 465-477.